Health
Ozempic Link to Rare Vision Loss Risk Confirmed in Study
- Risk of eye condition remains low; patients should be aware
- NAION occurs when loss of blood flow damages optic nerve
This article is for subscribers only.
Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that backs up Harvard University research published earlier this year.
Diabetes patients who used Ozempic were more than twice as likely to be diagnosed with the rare condition, called NAION, than those who took another type of diabetes drug, according to a team of researchers who studied years of patient records from Denmark and Norway. The study wasn’t able to determine whether there was a similar impact among people taking Ozempic’s sister drug, Wegovy, for obesity.